You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNadolol
Accession NumberDB01203  (APRD00301)
TypeSmall Molecule
GroupsApproved
Description

A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem]

Structure
Thumb
Synonyms
Corgard
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Corgardtablet40 mg/1oralUs World Meds, Llc2016-04-01Not applicableUs
Corgardtablet80 mg/1oralPfizer Laboratories Div Pfizer Inc1979-12-10Not applicableUs
Corgardtablet20 mg/1oralUs World Meds, Llc2016-04-01Not applicableUs
Corgardtablet40 mg/1oralPfizer Laboratories Div Pfizer Inc1979-12-10Not applicableUs
Corgardtablet20 mg/1oralPfizer Laboratories Div Pfizer Inc1979-12-10Not applicableUs
Corgardtablet80 mg/1oralUs World Meds, Llc2016-04-01Not applicableUs
Corgard Tab 160mgtablet160 mgoralBristol Myers Squibb Canada1981-12-312004-10-29Canada
Corgard Tab 40mgtablet40 mgoralBristol Myers Squibb Canada1984-12-312006-05-29Canada
Corgard Tab 80mgtablet80 mgoralBristol Myers Squibb Canada1979-12-312006-10-25Canada
Nadololtablet20 mg/1oralGreenstone LLC2014-04-28Not applicableUs
Nadololtablet40 mgoralAa Pharma Inc1988-12-31Not applicableCanada
Nadololtablet160 mgoralAa Pharma Inc1988-12-31Not applicableCanada
Nadololtablet80 mg/1oralGreenstone LLC2014-04-28Not applicableUs
Nadololtablet80 mgoralAa Pharma Inc1988-12-31Not applicableCanada
Nadololtablet40 mg/1oralGreenstone LLC2014-04-28Not applicableUs
Nadolol-160 Tab 160mgtablet160 mgoralPro Doc Limitee1989-12-312014-07-24Canada
Nadolol-40 Tab 40mgtablet40 mgoralPro Doc Limitee1989-12-312015-07-10Canada
Nadolol-80 Tab 80mgtablet80 mgoralPro Doc Limitee1989-12-312015-07-10Canada
Ratio-nadolol Tab 160mgtablet160 mgoralRatiopharm Inc Division Of Teva Canada Limited1989-12-312006-08-04Canada
Ratio-nadolol Tab 40mgtablet40 mgoralRatiopharm Inc Division Of Teva Canada Limited1989-12-312006-08-04Canada
Ratio-nadolol Tab 80mgtablet80 mgoralRatiopharm Inc Division Of Teva Canada Limited1989-12-312006-08-04Canada
Teva-nadololtablet80 mgoralTeva Canada Limited1994-12-31Not applicableCanada
Teva-nadololtablet40 mgoralTeva Canada Limited1994-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nadololtablet40 mg/1oralRebel Distributors Corp2011-01-18Not applicableUs
Nadololtablet40 mg/1oralAmerican Health Packaging2014-04-012015-12-31Us
Nadololtablet20 mg/1oralTeva Pharmaceuticals USA Inc2008-11-03Not applicableUs
Nadololtablet40 mg/1oralMylan Institutional Inc.1994-07-12Not applicableUs
Nadololtablet40 mg/1oralCamber, Pharmaceuticals Inc2016-01-27Not applicableUs
Nadololtablet20 mg/1oralSandoz Inc2008-10-01Not applicableUs
Nadololtablet20 mg/1oralBlue Point Laboratories2014-02-05Not applicableUs
Nadololtablet20 mg/1oralRebel Distributors Corp2011-01-18Not applicableUs
Nadololtablet20 mg/1oralAmerican Health Packaging2014-04-012015-12-31Us
Nadololtablet40 mg/1oralMylan Pharmaceuticals Inc.1993-10-31Not applicableUs
Nadololtablet40 mg/1oralBlue Point Laboratories2014-02-05Not applicableUs
Nadololtablet20 mg/1oralRebel Distributors Corp2008-10-01Not applicableUs
Nadololtablet20 mg/1oralAvera Mc Kennan Hospital2015-08-18Not applicableUs
Nadololtablet80 mg/1oralCipla USA Inc.2016-02-23Not applicableUs
Nadololtablet80 mg/1oralMylan Pharmaceuticals Inc.1993-10-31Not applicableUs
Nadololtablet80 mg/1oralBlue Point Laboratories2014-02-05Not applicableUs
Nadololtablet80 mg/1oralRebel Distributors Corp2008-10-01Not applicableUs
Nadololtablet40 mg/1oralDispensing Solutions, Inc.2008-10-01Not applicableUs
Nadololtablet40 mg/1oralCipla USA Inc.2016-02-23Not applicableUs
Nadololtablet20 mg/1oralMylan Pharmaceuticals Inc.1993-10-31Not applicableUs
Nadololtablet20 mg/1oralPhysicians Total Care, Inc.2005-05-16Not applicableUs
Nadololtablet40 mg/1oralRebel Distributors Corp2008-10-01Not applicableUs
Nadololtablet80 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Nadololtablet80 mg/1oralTeva Pharmaceuticals USA Inc2008-11-03Not applicableUs
Nadololtablet40 mg/1oralPhysicians Total Care, Inc.2010-01-14Not applicableUs
Nadololtablet20 mg/1oralCipla USA Inc.2016-02-23Not applicableUs
Nadololtablet80 mg/1oralSandoz Inc2008-10-01Not applicableUs
Nadololtablet40 mg/1oralAmerican Health Packaging2014-04-14Not applicableUs
Nadololtablet20 mg/1oralMylan Institutional Inc.1994-07-12Not applicableUs
Nadololtablet20 mg/1oralCamber, Pharmaceuticals Inc2016-01-27Not applicableUs
Nadololtablet40 mg/1oralTeva Pharmaceuticals USA Inc2008-11-03Not applicableUs
Nadololtablet20 mg/1oralREMEDYREPACK INC.2013-02-22Not applicableUs
Nadololtablet80 mg/1oralCamber, Pharmaceuticals Inc2016-01-27Not applicableUs
Nadololtablet40 mg/1oralSandoz Inc2008-10-01Not applicableUs
Nadololtablet20 mg/1oralAmerican Health Packaging2014-04-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnabetNot Available
SolgolNot Available
Brand mixtures
NameLabellerIngredients
CorzidePfizer Laboratories Div Pfizer Inc
Corzide Tab W Nadolol 40mgSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.
Corzide Tab W Nadolol 80mgSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.
Nadolol and BendroflumethiazideImpax Generics
SaltsNot Available
Categories
UNIIFEN504330V
CAS number42200-33-9
WeightAverage: 309.4006
Monoisotopic: 309.194008357
Chemical FormulaC17H27NO4
InChI KeyInChIKey=VWPOSFSPZNDTMJ-UCWKZMIHSA-N
InChI
InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1
IUPAC Name
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
SMILES
CC(C)(C)NCC(O)COC1=CC=CC2=C1C[[email protected]](O)[[email protected]](O)C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.
KingdomOrganic compounds
Super ClassBenzenoids
ClassTetralins
Sub ClassNot Available
Direct ParentTetralins
Alternative Parents
Substituents
  • Tetralin
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-diol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension.
PharmacodynamicsNadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.
Mechanism of actionLike other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
Related Articles
AbsorptionAbsorption of nadolol after oral dosing is variable, averaging about 30 percent.
Volume of distributionNot Available
Protein binding30%
Metabolism

Not metabolized by the liver and excreted unchanged primarily by the kidneys.

Route of eliminationUnlike many other beta-adrenergic blocking agents, nadolol is not metabolized by the liver and is excreted unchanged, principally by the kidneys. Nadolol is excreted predominantly in the urine.
Half life14-24 hours
ClearanceNot Available
ToxicityOral, mouse: LD50 = 4500mg/kg. Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nadolol Action PathwayDrug actionSMP00303
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9788
Blood Brain Barrier-0.966
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8317
P-glycoprotein inhibitor IInhibitor0.6192
P-glycoprotein inhibitor IINon-inhibitor0.7842
Renal organic cation transporterNon-inhibitor0.8736
CYP450 2C9 substrateNon-substrate0.7934
CYP450 2D6 substrateSubstrate0.7284
CYP450 3A4 substrateNon-substrate0.5456
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8072
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8934
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.7972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Inhibitor0.5781
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tabletoral160 mg
Tabletoral20 mg/1
Tabletoral40 mg/1
Tabletoral80 mg/1
Tabletoral40 mg
Tabletoral80 mg
Prices
Unit descriptionCostUnit
Nadolol powder94.8USD g
Corgard 160 mg tablet4.4USD tablet
Corgard 80 mg tablet4.33USD tablet
Corgard 120 mg tablet3.96USD tablet
Corgard 40 mg tablet3.11USD tablet
Corgard 20 mg tablet3.04USD tablet
Nadolol 160 mg tablet2.25USD tablet
Nadolol 80 mg tablet1.45USD tablet
Apo-Nadol 160 mg Tablet1.26USD tablet
Nadolol 40 mg tablet1.07USD tablet
Naldol 80 mg tablet1.03USD tablet
Nadolol 20 mg tablet0.92USD tablet
Apo-Nadol 80 mg Tablet0.37USD tablet
Novo-Nadolol 80 mg Tablet0.37USD tablet
Apo-Nadol 40 mg Tablet0.26USD tablet
Novo-Nadolol 40 mg Tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point124-136 °CPhysProp
water solubility8330 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.81SANGSTER (1994)
Caco2 permeability-5.41ADME Research, USCD
pKa9.67MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility2.25 mg/mLALOGPS
logP1.23ALOGPS
logP0.87ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)13.59ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area81.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity85.53 m3·mol-1ChemAxon
Polarizability34.63 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US3935267
General ReferencesNot Available
External Links
ATC CodesC07AA12C07BA12
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.1 KB)
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Nadolol.
AcetylcholineThe risk or severity of adverse effects can be increased when Nadolol is combined with Acetylcholine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nadolol.
AlfentanilAlfentanil may increase the bradycardic activities of Nadolol.
AlfuzosinNadolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Nadolol.
AmifostineNadolol may increase the hypotensive activities of Amifostine.
AminophyllineNadolol may decrease the activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Nadolol.
ArformoterolNadolol may decrease the activities of Arformoterol.
ArticaineNadolol may increase the activities of Articaine.
BethanecholThe risk or severity of adverse effects can be increased when Nadolol is combined with Bethanechol.
BretyliumBretylium may increase the bradycardic activities of Nadolol.
BrimonidineBrimonidine may increase the antihypertensive activities of Nadolol.
BromocriptineNadolol may increase the vasoconstricting activities of Bromocriptine.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Nadolol.
ButabarbitalButabarbital may increase the hypotensive activities of Nadolol.
ButethalButethal may increase the hypotensive activities of Nadolol.
CabergolineNadolol may increase the vasoconstricting activities of Cabergoline.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Nadolol.
CarbacholThe risk or severity of adverse effects can be increased when Nadolol is combined with Carbachol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Nadolol.
CeritinibNadolol may increase the bradycardic activities of Ceritinib.
CevimelineThe risk or severity of adverse effects can be increased when Nadolol is combined with Cevimeline.
ChlorpropamideNadolol may increase the hypoglycemic activities of Chlorpropamide.
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Nadolol.
ColesevelamColesevelam can cause a decrease in the absorption of Nadolol resulting in a reduced serum concentration and potentially a decrease in efficacy.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nadolol.
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Nadolol.
DiazoxideDiazoxide may increase the hypotensive activities of Nadolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Nadolol.
DiflunisalDiflunisal may decrease the antihypertensive activities of Nadolol.
DigoxinNadolol may increase the bradycardic activities of Digoxin.
DihydroergotamineNadolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydrotachysterolNadolol may increase the hypercalcemic activities of Dihydrotachysterol.
DiltiazemDiltiazem may increase the hypotensive activities of Nadolol.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Nadolol.
DipyridamoleDipyridamole may increase the bradycardic activities of Nadolol.
DisopyramideDisopyramide may increase the bradycardic activities of Nadolol.
DonepezilDonepezil may increase the bradycardic activities of Nadolol.
DopamineNadolol may increase the activities of Dopamine.
DoxazosinNadolol may increase the orthostatic hypotensive activities of Doxazosin.
DronedaroneDronedarone may increase the bradycardic activities of Nadolol.
DuloxetineNadolol may increase the orthostatic hypotensive activities of Duloxetine.
DyphyllineNadolol may decrease the activities of Dyphylline.
EdrophoniumEdrophonium may increase the bradycardic activities of Nadolol.
EpinephrineNadolol may increase the activities of Epinephrine.
Ergoloid mesylateNadolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineNadolol may increase the vasoconstricting activities of Ergonovine.
ErgotamineNadolol may increase the vasoconstricting activities of Ergotamine.
EsmololEsmolol may increase the bradycardic activities of Nadolol.
EthanolEthanol may increase the orthostatic hypotensive activities of Nadolol.
EtodolacEtodolac may decrease the antihypertensive activities of Nadolol.
FenoprofenFenoprofen may decrease the antihypertensive activities of Nadolol.
FenoterolNadolol may decrease the activities of Fenoterol.
FentanylFentanyl may increase the bradycardic activities of Nadolol.
FingolimodNadolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nadolol.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Nadolol.
FlunisolideFlunisolide may increase the hypokalemic activities of Nadolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Nadolol.
Fluticasone PropionateNadolol may decrease the activities of Fluticasone Propionate.
FormoterolNadolol may decrease the activities of Formoterol.
GalantamineGalantamine may increase the bradycardic activities of Nadolol.
GliclazideNadolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideNadolol may increase the hypoglycemic activities of Glimepiride.
GlipizideNadolol may increase the hypoglycemic activities of Glipizide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Nadolol.
GlyburideNadolol may increase the hypoglycemic activities of Glyburide.
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Nadolol.
GuanidineThe risk or severity of adverse effects can be increased when Nadolol is combined with Guanidine.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Nadolol.
HexobarbitalHexobarbital may increase the hypotensive activities of Nadolol.
IbuprofenIbuprofen may decrease the antihypertensive activities of Nadolol.
IndacaterolNadolol may decrease the activities of Indacaterol.
IndomethacinIndomethacin may decrease the antihypertensive activities of Nadolol.
InfliximabInfliximab may decrease the antihypertensive activities of Nadolol.
Insulin AspartNadolol may increase the hypoglycemic activities of Insulin Aspart.
Insulin DegludecNadolol may increase the hypoglycemic activities of Insulin degludec.
Insulin DetemirNadolol may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineNadolol may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineNadolol may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanNadolol may increase the hypoglycemic activities of Insulin Regular.
Insulin LisproNadolol may increase the hypoglycemic activities of Insulin Lispro.
Ipratropium bromideNadolol may decrease the activities of Ipratropium bromide.
IvabradineNadolol may increase the bradycardic activities of Ivabradine.
KetoprofenKetoprofen may decrease the antihypertensive activities of Nadolol.
KetorolacKetorolac may decrease the antihypertensive activities of Nadolol.
LacosamideNadolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LevodopaNadolol may increase the orthostatic hypotensive activities of Levodopa.
LevonordefrinNadolol may increase the activities of Levonordefrin.
LicoriceLicorice may increase the hypokalemic activities of Nadolol.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Nadolol.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Nadolol.
LumacaftorThe serum concentration of Nadolol can be decreased when it is combined with Lumacaftor.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Nadolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Nadolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Nadolol.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Nadolol.
MethacholineThe risk or severity of adverse effects can be increased when Nadolol is combined with Methacholine.
MethohexitalMethohexital may increase the hypotensive activities of Nadolol.
MethyldopaMethyldopa may increase the atrioventricular blocking (AV block) activities of Nadolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nadolol.
MidodrineNadolol may increase the bradycardic activities of Midodrine.
MolsidomineMolsidomine may increase the hypotensive activities of Nadolol.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nadolol.
MoxonidineMoxonidine may increase the hypotensive activities of Nadolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Nadolol.
NaproxenNaproxen may decrease the antihypertensive activities of Nadolol.
NeostigmineNeostigmine may increase the bradycardic activities of Nadolol.
NicorandilNicorandil may increase the hypotensive activities of Nadolol.
NifedipineNifedipine may increase the hypotensive activities of Nadolol.
NorepinephrineNadolol may increase the activities of Norepinephrine.
ObinutuzumabNadolol may increase the hypotensive activities of Obinutuzumab.
OctreotideOctreotide may increase the bradycardic activities of Nadolol.
OlodaterolNadolol may decrease the activities of Olodaterol.
OrciprenalineNadolol may decrease the activities of Orciprenaline.
OxaprozinOxaprozin may decrease the antihypertensive activities of Nadolol.
ParoxetineParoxetine may increase the activities of Nadolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Nadolol.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nadolol.
PerindoprilNadolol may increase the hypotensive activities of Perindopril.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Nadolol.
PhenoxybenzamineNadolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.
PhentolamineNadolol may increase the orthostatic hypotensive activities of Phentolamine.
PhysostigminePhysostigmine may increase the bradycardic activities of Nadolol.
PilocarpineThe risk or severity of adverse effects can be increased when Nadolol is combined with Pilocarpine.
PirbuterolNadolol may decrease the activities of Pirbuterol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Nadolol.
PrazosinNadolol may increase the orthostatic hypotensive activities of Prazosin.
PrimidonePrimidone may increase the hypotensive activities of Nadolol.
ProcyclidineThe serum concentration of Nadolol can be increased when it is combined with Procyclidine.
PyridostigminePyridostigmine may increase the bradycardic activities of Nadolol.
QuinineQuinine may increase the hypotensive activities of Nadolol.
RacepinephrineNadolol may increase the activities of Racepinephrine.
RanolazineThe serum concentration of Nadolol can be increased when it is combined with Ranolazine.
RegorafenibRegorafenib may increase the bradycardic activities of Nadolol.
RemifentanilRemifentanil may increase the bradycardic activities of Nadolol.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Nadolol.
ReserpineReserpine may increase the hypotensive activities of Nadolol.
RisperidoneNadolol may increase the hypotensive activities of Risperidone.
RituximabNadolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Nadolol.
RuxolitinibRuxolitinib may increase the bradycardic activities of Nadolol.
SalbutamolNadolol may decrease the activities of Salbutamol.
SalmeterolNadolol may decrease the activities of Salmeterol.
SaquinavirThe serum concentration of Nadolol can be increased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Nadolol.
SecobarbitalSecobarbital may increase the hypotensive activities of Nadolol.
SilodosinNadolol may increase the orthostatic hypotensive activities of Silodosin.
SufentanilSufentanil may increase the bradycardic activities of Nadolol.
SulindacSulindac may decrease the antihypertensive activities of Nadolol.
TacrineTacrine may increase the bradycardic activities of Nadolol.
TadalafilTadalafil may increase the antihypertensive activities of Nadolol.
TamsulosinNadolol may increase the orthostatic hypotensive activities of Tamsulosin.
TerazosinNadolol may increase the orthostatic hypotensive activities of Terazosin.
TerbutalineNadolol may decrease the activities of Terbutaline.
TesmilifeneThe serum concentration of Nadolol can be decreased when it is combined with Tesmilifene.
TheophyllineNadolol may decrease the activities of Theophylline.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Nadolol.
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Nadolol.
TofacitinibTofacitinib may increase the bradycardic activities of Nadolol.
TolazamideNadolol may increase the hypoglycemic activities of Tolazamide.
TolbutamideNadolol may increase the hypoglycemic activities of Tolbutamide.
TolmetinTolmetin may decrease the antihypertensive activities of Nadolol.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Nadolol.
TreprostinilTreprostinil may increase the hypotensive activities of Nadolol.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nadolol.
VardenafilVardenafil may increase the antihypertensive activities of Nadolol.
VerapamilVerapamil may increase the hypotensive activities of Nadolol.
VilanterolNadolol may decrease the activities of Vilanterol.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nadolol.
YohimbineYohimbine may decrease the antihypertensive activities of Nadolol.
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Magnesium, potassium and zinc needs increased.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Wheeldon NM, McDevitt DG, Lipworth BJ: The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1994 Aug;38(2):103-8. [PubMed:7981009 ]
  3. Koshiji M, Ito H, Minatoguchi S, Watanabe H, Imai Y, Kakami M, Hirakawa S: A comparison of guanfacine, bunazosin, atenolol and nadolol on blood pressure and plasma noradrenaline responses to cold pressor testing. Clin Exp Pharmacol Physiol. 1992 Jul;19(7):481-8. [PubMed:1354084 ]
  4. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496 ]
  5. Varma DR: Ligand-independent negative chronotropic responses of rat and mouse right atria to beta-adrenoceptor antagonists. Can J Physiol Pharmacol. 1999 Dec;77(12):943-9. [PubMed:10606440 ]
  6. Wheeldon NM, McDevitt DG, Lipworth BJ: Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man. Br J Clin Pharmacol. 1994 Apr;37(4):363-9. [PubMed:7912539 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Wheeldon NM, McDevitt DG, Lipworth BJ: The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1994 Aug;38(2):103-8. [PubMed:7981009 ]
  3. Ozakca I, Arioglu E, Guner S, Altan VM, Ozcelikay AT: Role of beta-3-adrenoceptor in catecholamine-induced relaxations in gastric fundus from control and diabetic rats. Pharmacology. 2007;80(4):227-38. Epub 2007 Jul 6. [PubMed:17622774 ]
  4. Liu YL, Toubro S, Astrup A, Stock MJ: Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes Relat Metab Disord. 1995 Sep;19(9):678-85. [PubMed:8574280 ]
  5. Wheeldon NM, McDevitt DG, Lipworth BJ: Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol. Br J Clin Pharmacol. 1992 Apr;33(4):411-6. [PubMed:1349493 ]
  6. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9. [PubMed:8953513 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23